HIV

IRP Research Yields Life-Changing Treatments

Highlighting Drugs and Vaccines Stemming from NIH Discoveries

syringe and vials of medicine

On May 3, more than six decades of IRP research culminated in the U.S. Food and Drug Administration (FDA) approving the world’s first vaccine for respiratory syncytial virus (RSV), a disease that puts tens of thousands of Americans in the hospital each year and kills thousands. While the new vaccine, called Arexy, has been getting all the headlines recently, it is only the latest example of a slew of FDA-approved medications and vaccines that might never have existed without the tireless efforts of scientists at NIH.

Indeed, a recently published study led by Mark Rohrbaugh, Ph.D., J.D., a special advisor in the NIH Office of Science Policy, found that inventions developed at NIH have contributed to more FDA-approved products than those created at any other nonprofit research institution in the world over the past five decades. NIH tops the study’s list with 27 FDA-approved products, six more than the study attributed to the combined efforts of all the schools in the University of California system.

Teaming Up to Tackle Engineering Challenges

Innovation Awards Accelerate Development of New Research Techniques

scientist working with a robotic arm

Scientists spend years, even decades, intensely studying a specific disease or biological system, an approach that yields unrivaled knowledge. However, many important scientific questions require a deep understanding of several subjects. As a result, the IRP has numerous programs dedicated to encouraging scientists with different areas of expertise to work together.

One such program is the NIH Director’s Challenge Innovation Awards, which funds innovative, high-impact projects that require the cooperation of researchers in more than one of NIH’s Institutes and Centers. This year, the program selected six promising proposals with one foot in the disciplines of biology and medicine and another in engineering or the physical sciences.

Understanding the Foundations of Immune Defenses

IRP’s Mary Carrington Elected to the American Academy of Arts and Sciences for Insights Into Immune System Variations

Dr. Mary Carrington

Some people never seem to get sick, while others catch a new bug of some sort every other week. Humans are immensely variable both in their capacity to shrug off illness and in the ways their bodies respond to medical treatments. IRP senior investigator Mary Carrington, Ph.D., has spent her entire career exploring the biological roots of these differences, and the discoveries she has made earned her election to the American Academy of Arts and Sciences earlier this year.

Leading the Charge Against Infectious Disease

Government Awards Recognize H. Clifford Lane’s Four Decades of Research Achievements

Dr. H. Clifford Lane

The remarkable career of H. Clifford Lane, M.D., might have gone very differently if a NIH scientist hadn’t accidentally eavesdropped on Dr. Lane’s conversation with a colleague in 1979. After hearing Dr. Lane mention that he had missed the deadline to apply for a position at NIH, the NIH researcher made some calls and discovered a spot there had just opened up — one that was perfect for Dr. Lane, who would spend the ensuing decades conducting life-saving research to understand and combat some of the world’s most dangerous infectious diseases.

Now the Clinical Director at the National Institute for Allergy and Infectious Disease (NIAID), Dr. Lane has been named a finalist for the 2022 Samuel J. Heyman Service to America Medals’ Career Achievement Award in recognition of his crucial contributions to the fight against HIV/AIDS, Ebola, COVID-19, and other illnesses. Also known as the “Sammies,” the awards recognize federal employees who are “breaking down barriers, overcoming huge challenges, and getting results.”

NIH Mourns the Passing of Thomas A. Waldmann

Dr. Thomas A. Waldmann

The NIH community is profoundly saddened by the recent passing of Thomas A. Waldmann, M.D., Chief Emeritus of the Lymphoid Malignancies Branch and NIH Distinguished Investigator.

Considered a giant in the field, Tom was a renowned immunologist whose more than 60-year career at the National Cancer Institute led to numerous high-impact discoveries that advanced the fields of organ transplantation, autoimmune disease and cancer. He was a leader in the study of cytokines and their receptors and of monoclonal antibodies, now a dominant form of cancer immunotherapy.

NIH Summer Interns Show Off in Poster Exhibitions

Budding Scientists Present Their Research During Three-Day Virtual Event

Deeya Garg

Although NIH’s 2021 Summer Internship Program (SIP) was fully virtual this year, that didn’t stop the hundreds of participating high school, college, and graduate students from contributing to a variety of important IRP research projects. More than 500 students who worked in NIH labs this summer presented their work during this year’s Summer Presentation Week, which took place August 3-5.

I sifted through the lengthy list of presenters at the event and spoke with a diverse group of young men and women who spent their summers expanding our knowledge of human health and biology. Read on to learn about these promising future scientists and doctors and the research they completed this summer.

Global Scientists Come Together at the National Institutes of Health

Individuals From Around the World Drive IRP Breakthroughs

Dr. Flossie Wong-Staal

Come to NIH and you’ll hear many accents. Scientists from around the world have always contributed significantly to the NIH mission. The resulting diversity of backgrounds and perspectives makes the NIH Intramural Research Program an extremely stimulating and productive environment. Read on to learn about some of the many scientists of the past and present who brought their talents from abroad to one of the world’s leading institutions for biomedical research.

Study Identifies How Suppressed HIV Keeps Immune System on Edge

Findings Point to Approaches for Staving Off Health Problems in Infected Individuals

HIV-infected T cell

Over the four decades since it mysteriously began destroying the immune systems of Americans in New York and California, HIV has proven to be a frustratingly wily opponent for scientists. Even today, when treatments can fully suppress the virus in infected individuals, it continues to harm their health. A new IRP study has identified several ways dormant HIV might chronically stimulate the immune system, suggesting potential avenues for preventing the health problems that causes.

An Ebola Therapy Two Decades in the Making

IRP Researcher Nancy Sullivan Led Development of Cutting-Edge Treatment

a volunteer receives an infusion of an experimental Ebola therapy during a phase I clinical trial

Twenty-four years before the novel coronavirus began spreading in Wuhan, China, an outbreak of another deadly virus burned through the city of Kikwit in what is now the Democratic Republic of Congo. Between January and August of 1995, 316 people are thought to have contracted Ebola, and 252 of them died. More than a decade later, a team of NIH infectious disease scientists would track down one of the survivors and use a sample of the individual’s blood to produce one of the first effective treatments for Ebola.

Remembrances: Flossie Wong-Staal

Dr. Flossie Wong-Staal

Flossie Wong-Staal — a pioneering former NIH scientist, a major figure in the discovery of HIV, and the first to clone that virus — died on July 8, 2020. She was 73 years old.

Flossie arrived at the NIH as a Visiting Fellow in 1973 and began working in the National Cancer Institute (NCI) lab of Robert Gallo, who was on the cusp of a remarkable string of discoveries. Flossie, with her Ph.D. from UCLA in molecular biology, became the ideal complement to Bob Gallo's medical-based scientific intuition, and the two would go on to co-author more than 100 journal articles over the next 20 years.